Identification and Evaluation of Coronavirus Replicase Inhibitors Using a Replicon Cell Line

@article{Scandella2006IdentificationAE,
  title={Identification and Evaluation of Coronavirus Replicase Inhibitors Using a Replicon Cell Line},
  author={Elke Scandella and Klara Kristin Eriksson and Tobias Hertzig and Christian Drosten and Li-li Chen and Chunshan Gui and Xiaomin Luo and Jianhua Shen and Xu Shen and Stuart G. Siddell and Burkhard Ludewig and Hualiang Jiang and Stephan G{\"u}nther and Volker Thiel},
  journal={The Nidoviruses},
  year={2006},
  volume={581},
  pages={609 - 613}
}
In order to provide a rapid and safe assay for the identification and evaluation of coronavirus replicase inhibitors, we have generated a non-cytopathic, selectable replicon RNA (based on human coronavirus 229E [HCoV-229E]) that can be stably maintained in eukaryotic cells. Stable, replicon RNA-containing cell lines that express green fluorescent protein (GFP) as a marker for coronavirus replication have been used to test the inhibitory effect of several compounds that are currently being… 
Plaque assay for human coronavirus NL63 using human colon carcinoma cells
TLDR
CaCo-2 cells support hCoV-NL63 better than LLC-MK2 cells and enable cytopathogenic plaque assays, which will be beneficial in antiviral screening, animal modelling of disease, and other experimental tasks.
In Silico Identification of Widely Used and Well Tolerated Drugs That May Inhibit SARSCov- 2 3C-like Protease and Viral RNA-Dependent RNA Polymerase Activities, and May Have Potential to Be Directly Used in Clinical Trials
TLDR
Analysis of docking results suggested that ergotamine, dihydroergotamine, bromocriptine, dutasteride, conivaptan, paliperidone, and tipranavir can bind to both enzymes with high affinity and have potential to be used in clinical trial for the treatment of SARS-CoV-2 infected patients.
In silico identification of widely used and well-tolerated drugs as potential SARS-CoV-2 3C-like protease and viral RNA-dependent RNA polymerase inhibitors for direct use in clinical trials
TLDR
Docking results suggest that ergotamine, dihydroergotamine, bromocriptine, dutasteride, conivaptan, paliperidone, and tipranavir can bind to both enzymes with high affinity, and could potentially to be used in clinical trials for the treatment of SARS-CoV-2-infected patients.
Nuclear Medicine in Times of COVID-19: How Radiopharmaceuticals Could Help to Fight the Current and Future Pandemics
TLDR
Several potential uses of nuclear medicine in the context of SARS-CoV-2 and COVID-19 are highlighted and how radiolabeled analogs of these compounds could facilitate antiviral drug development and translation to the clinic, reduce the incidence of late-stage failures and possibly provide the basis for radionuclide-based treatment strategies are described.
Virology Journal
  • 2004

References

SHOWING 1-10 OF 12 REFERENCES
Rapid identification of coronavirus replicase inhibitors using a selectable replicon RNA.
TLDR
This work has generated a non-cytopathic, selectable replicon RNA (based on human CoV 229E) that can be stably maintained in eukaryotic cells and mediates reporter gene expression as a marker for coronavirus replication, which will allow high throughput screening for SARS-CoV replicase inhibitors without the need to grow infectious SARs.
Cinanserin Is an Inhibitor of the 3C-Like Proteinase of Severe Acute Respiratory Syndrome Coronavirus and Strongly Reduces Virus Replication In Vitro
TLDR
It is demonstrated that the old drug cinanserin is an inhibitor of SARS-CoV replication, acting most likely via inhibition of the 3CL proteinase.
Coronavirus Main Proteinase (3CLpro) Structure: Basis for Design of Anti-SARS Drugs
TLDR
Molecular modeling suggests that available rhinovirus 3Cpro inhibitors may be modified to make them useful for treating SARS, and a homology model for SARS coronavirus (SARS-CoV) Mpro is constructed.
Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus.
TLDR
A reverse-genetic system is described for the generation of recombinant coronaviruses based upon the in vitro transcription of infectious RNA from a cDNA copy of the human coronavirus 229E genome that has been cloned and propagated in vaccinia virus.
Virus-encoded proteinases and proteolytic processing in the Nidovirales.
TLDR
This paper presents a meta-anatomy of the EMMARM, a probabilistic model of the immune response to EMT, which states that EMTs are more likely to attack the nervous system than the immune systems of mice.
Cinanserin (SQ. 10,643): a preliminary evaluation in chronic schizophrenic patients.
antoserotonin activity on uterus and on gastrointestinal, vascular, and respiratory systems of animals, Arch
  • Int. Pharmacodyn. Ther. 152, 132143
  • 1964
...
...